Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer

A useful candidate for small-cell lung cancer (SCLC) therapy is immune checkpoint blockade therapy targeting programmed death-1 (PD-1) and its ligand, PD-L1. Furthermore, rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate, and enhancer of zeste homologue...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Clin Oncol
Asıl Yazarlar: Saito, Motonobu, Saito, Katsuharu, Shiraishi, Kouya, Maeda, Daichi, Suzuki, Hiroyuki, Minamiya, Yoshihiro, Kono, Koji, Kohno, Takashi, Goto, Akiteru
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2018
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5776411/
https://ncbi.nlm.nih.gov/pubmed/29435295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1536
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller